Abstract 5702: An image-based approach to visualize ADC internalization and cytotoxicity in patient-derived organoids

Abstract Antibody-drug conjugates (ADCs) represent an emerging class of cancer therapies designed to address the limitations of traditional chemotherapy, particularly the toxicity that arises from healthy cells being exposed to cytotoxic agents. ADCs combine a target-specific monoclonal antibody with a cytotoxic payload, enabling selective delivery to cancer cells and significantly reducing adverse effects. HUB Patient-Derived Organoids (PDOs) are advanced 3D in vitro models derived from adult stem cells that faithfully replicate the architecture, genetics, and physiology of original patient tissues. By preserving patient-specific genetic and phenotypic traits, including surface marker expression, HUB has established a comprehensive and well-characterized biobank of tumor-derived PDOs. This biobank provides a powerful platform for translational research, drug discovery, and the development of targeted therapies. In this study, we present an organoid-based, image-based internalization assay that complements standard Cell Titer-Glo viability assays by enabling direct visualization of ADC internalization. This assay facilitates a deeper exploration of the mechanisms of action of ADCs. We pre-selected tumor-derived organoids based on HER2 expression, which was assessed using flow cytometry. After treating the organoids with FDA-approved HER2-targeting ADCs, we utilized the internalization assay to support the viability data and to define key parameters such as the timing of action, the effect of the payload, and whether cell death resulted from ADC internalization. Overall, these results reinforce the value of patient-derived organoids as a physiologically relevant preclinical platform for ADC development. They also highlight the suitability of the described image-based assay for investigating critical stages of ADC mechanisms, including internalization and payload activity. Citation Format: Daniele Mori, Javier Frias Aldeguer, Rene Overmeer, Sylvia F. Boj, . An image-based approach to visualize ADC internalization and cytotoxicity in patient-derived organoids [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 5702.

Authors

Institutions

Publication Details

Journal
Cancer Research
Published
2026-04-03
DOI
https://doi.org/10.1158/1538-7445.am2026-5702
Primary Topic
HER2/EGFR in Cancer Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Abstract 5702: An image-based approach to visualize ADC internalization and cytotoxicity in patient-derived organoids

Javier Frias Aldeguer, René Overmeer, Daniele Mori, Sylvia F. Boj
Cancer Research
HER2/EGFR in Cancer Research
article

Abstract 5702: An image-based approach to visualize ADC internalization and cytotoxicity in patient-derived organoids

Javier Frias Aldeguer, René Overmeer, Daniele Mori, Sylvia F. Boj
article en

Abstract

Abstract Antibody-drug conjugates (ADCs) represent an emerging class of cancer therapies designed to address the limitations of traditional chemotherapy, particularly the toxicity that arises from healthy cells being exposed to cytotoxic agents. ADCs combine a target-specific monoclonal antibody with a cytotoxic payload, enabling selective delivery to cancer cells and significantly reducing adverse effects. HUB Patient-Derived Organoids (PDOs) are advanced 3D in vitro models derived from adult stem cells that faithfully replicate the architecture, genetics, and physiology of original patient tissues. By preserving patient-specific genetic and phenotypic traits, including surface marker expression, HUB has established a comprehensive and well-characterized biobank of tumor-derived PDOs. This biobank provides a powerful platform for translational research, drug discovery, and the development of targeted therapies. In this study, we present an organoid-based, image-based internalization assay that complements standard Cell Titer-Glo viability assays by enabling direct visualization of ADC internalization. This assay facilitates a deeper exploration of the mechanisms of action of ADCs. We pre-selected tumor-derived organoids based on HER2 expression, which was assessed using flow cytometry. After treating the organoids with FDA-approved HER2-targeting ADCs, we utilized the internalization assay to support the viability data and to define key parameters such as the timing of action, the effect of the payload, and whether cell death resulted from ADC internalization. Overall, these results reinforce the value of patient-derived organoids as a physiologically relevant preclinical platform for ADC development. They also highlight the suitability of the described image-based assay for investigating critical stages of ADC mechanisms, including internalization and payload activity. Citation Format: Daniele Mori, Javier Frias Aldeguer, Rene Overmeer, Sylvia F. Boj, . An image-based approach to visualize ADC internalization and cytotoxicity in patient-derived organoids [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 5702.

Cancer ResearchVol. 86(7_Supplement)
SNV Netherlands Development Organisation (NL)
Good health and well-being
Openalex Percentile: Top 9%
HER2/EGFR in Cancer Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.